Abstract: Compounds of the formula Ia***** in which the substituents have the definitions provided in the specification, are novel, effective PDE4 inhibitors.

Abstract: Compounds of the formula Ia***** in which the substituents have the definitions provided in the specification, are novel, effective PDE4 inhibitors.

Abstract: Dosage forms for oral administration of a PDE 4 inhibitor whose solubility is slight are described. They contain PVP as binder.

Abstract: Use of an adsorbent and a sealed package (e.g. an overwrap) to protect a pharmaceutical product in a solid state in the presence of a reducing sugar.

Abstract: The invention relates to the use of Roflumilast and/or Roflumilast N-Oxide for the treatment of diabetes mellitus and accompanying disorders thereof. The invention additionally relates to combinations of Roflumilast and/or Roflumilast N-Oxide with other active agents for the treatment of diabetes mellitus.

Abstract: The compounds of Formula (I), are novel effective inhibitors of the type 4 phosphodiesterase.

Abstract: Compounds of the formula I in which the substituents have the definitions provided in the specification, are novel, effective PDE4 inhibitors.

Abstract: The present invention relates to the field of pharmaceutical technology and describes a pharmaceutical preparation in the form of a paste comprising an acid-labile active ingredient, in particular an acid-labile proton pump inhibitor. The invention also relates to processes for producing the paste. The paste is particularly suitable for administering acid-labile active ingredients to animals or to people who have difficulty taking solid dosage forms such as tablets or capsules.

Abstract: Dosage forms for oral administration of the magnesium salt of (S)-pantoprazole are described.

Abstract: The compounds of formula (I) in which R1, R2 and R3 have the meanings as given in the description are novel effective PDE2 inhibitors.

Abstract: The present invention relates to the field of pharmaceutical technology and describes a novel advantageous preparation for an active ingredient. The novel preparation is suitable for producing a large number of pharmaceutical dosage forms. In the new preparation, an active ingredient is present essentially uniformly dispersed in an excipient matrix composed of one or more excipients selected from the group of fatty alcohols, triglycerides, partial triglycerides and fatty acid esters.

Abstract: Dosage forms for oral administration of a PDE 4 inhibitor whose solubility is slight are described. They contain PVP as binder.

Abstract: Provided herein is a stable pharmaceutical product comprising a dry powder inhalation device, and a pharmaceutical composition that comprises R,R-Formoterol L-tartrate salt, in particular crystalline R,R-formoterol L-tartrate; and ciclesonide.

Abstract: A filtering device comprises a filtering means (8); a first plate-like element (4) disposed on the filtering means (8) and having at least one bore (4a); a second plate-like element (5) disposed below the filtering means (8) and having at least one bore (5a); and a plate-like adapter element (1, 2) disposed on the first plate-like element (4) and having at least one bore (1a, 2a). At least one adapter means (1b, 2b, 3) is disposed on the plate-like adapter element (1, 2) on a side opposite to the first plate-like element (4) and is open to the bore (1a, 2a) of the plate-like adapter element (1, 2). The at least one adapter means (1b, 2b, 3) is adapted for connection with a container containing a fluid to be filtered.

Abstract: The subject matter of this application relates to the combination of ciclesonide with an antihistamine.

Abstract: The subject matter of this application relates to the combination of ciclesonide or an epimer thereof with R,R-formoterol or a salt, or a hydrate of a salt thereof.

Abstract: Provided herein is a stable pharmaceutical product comprising a dry powder inhalation device, and a pharmaceutical composition that comprises R,R-Formoterol L-tartrate salt, in particular crystalline R,R-formoterol L-tartrate; and ciclesonide.

Abstract: Disclosed is a method of treatment of COPD by oral administration of roflumilast.

Abstract: Compounds of a certain formula I, in which Ra and Rb have the meanings indicated in the description, are novel effective compounds with anti-proliferative and apoptosis inducing activity.

Abstract: To provide an access route which is leaktight and at the same time permits mobility and exact positioning of an instillation catheter (6), an arrangement comprising an instillation catheter (6) and a connector piece (1) for attachment to a tracheal or endotracheal tube is proposed. The connector piece (1) has a distal end (1a) for attachment to the tube, and a proximal end (1b) for attachment to a ventilation and/or suction device and comprises a branch (5) which serves for insertion of the catheter (6) and in which a valve (2) is arranged. The valve (2) is made, at least in some areas, from an elastically deformable material and can be opened by insertion of the catheter (6). The valve further comprises a proximal through-opening (21) whose inner wall has a means allowing sealing against axial flow of fluid between catheter (6) and inner wall, and, in the distal direction from the through-opening, it has a beak section (22) which, at its beak tip (23), has a normally closed slit (24).